Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| α-epidermal growth factor, human | Recombinant human epidermal growth factor has the same structure as the human epidermal growth factor. EGF binds to epidermal growth factor receptor (EGFR) and stimulates cell growth and proliferation. Recombinant human epidermal growth factor is approved for the treatment of diabetic foot ulcers. Uses: The treatment of diabetic foot ulcers. Group: Pharmaceutical. Alternative Names: Human EGF; Nepidermin. CAS No. 62253-63-8. Pack Sizes: 1 mg. Product ID: BAT-010173. Molecular formula: C270H401N73O83S7. Mole weight: 6222. Custom synthesis is available. Send your inquiries for more information. |  London |
| 5,7-Dihydrox -4'-methoxyisoflavone | Biochanin A, an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM. Uses: Anti-tumorigenesis, anti-oxidation, and anti-inflammatory. Group: Pharmaceutical. Alternative Names: Biochanin; Pratensol; olmelin; 4'-methyl Genistein; 4-methylGenistein; 5,7-dihydroxy-4'-Methoxyisoflavone; NSC 123538; NSC-123538; NSC123538. CAS No. 491-80-5. Pack Sizes: 5 g. Product ID: NP1827. Molecular formula: C16H12O5. Mole weight: 284.26. Custom synthesis is available. Send your inquiries for more information. | London |
| AC480 | AC480, also known as BMS-599626, is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respectively) with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. Group: Pharmaceutical. Alternative Names: BMS-599626; BMS 599626; BMS599626; AC 480; AC-480; Carbamic acid, N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (3S)-3-morpholinylmethyl ester; (3S)-3-Morpholinylmethyl N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate; Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (3S)-3-morpholinylmethyl ester; N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid, (3S)-3-morpholinylmethyl ester. CAS No. 714971-09-2. Pack Sizes: 1mg;1g;10g. Product ID: B0084-259278. Molecular formula: C27H27FN8O3. Mole weight: 530.55. Custom synthesis is available. Send your inquiries for more information. | London |
| AEE-788 | AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. Group: Pharmaceutical. Alternative Names: AEE 788; AEE788; 6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. CAS No. 497839-62-0. Pack Sizes: 10 mg. Product ID: B0084-258485. Molecular formula: C27H32N6. Mole weight: 440.595. Custom synthesis is available. Send your inquiries for more information. | London |
| AG 126 | Tyrphostins are protein tyrosine kinase inhibitors developed to inhibit cell growth through blocking the activity of certain GFRK (growth factor receptor kinases). AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 μM. It also inhibits the production of TNF-α (tumor necrosis factor-α), attenuating signaling through NF-κB, the induced expression of COX-2 and iNOS, and the inflammatory response in animal models. AG 126 is a poor inhibitor of epidermal GFRK with IC50 of 450 μM and platelet-derived GFRK with IC50 > 100 μM. AG 126 may represent a new approach for the therapy of inflammation. Uses: Anti- inflammation. Group: Pharmaceutical. Alternative Names: AG126; AG-126; Tyrphostin AG 126; UNII-7YA4AMD1JC; Tyrphostin A 10; alpha-Cyano-(3-hydroxy-4-nitro)cinnamonitrile. CAS No. 118409-62-4. Pack Sizes: 100 mg. Product ID: B1370-195904. Molecular formula: C10H5N3O3. Mole weight: 215.16. Custom synthesis is available. Send your inquiries for more information. | London |
| AG-1557 | AG-1557 is an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Group: Pharmaceutical. Alternative Names: AG-1557; AG 1557; AG1557; N-(3-Iodophenyl)-6,7-dimethoxyquinazolin-4-amine. CAS No. 189290-58-2. Pack Sizes: 50 mg. Product ID: B0084-284805. Molecular formula: C16H14IN3O2. Mole weight: 407.211. Custom synthesis is available. Send your inquiries for more information. | London |
| AV-412 | AV-412 is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may suppress tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to first-generation kinase inhibitors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. Group: Pharmaceutical. Alternative Names: AV 412; AV412; N-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide. CAS No. 451492-95-8. Pack Sizes: 20 mg. Product ID: B0084-324573. Molecular formula: C27H28ClFN6O. Mole weight: 507.01. Custom synthesis is available. Send your inquiries for more information. | London |
| AZD3759 | AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. Group: Pharmaceutical. Alternative Names: AZD3759; AZD-3759; AZD 3759. CAS No. 1626387-80-1. Pack Sizes: 1 g. Product ID: B0084-470884. Molecular formula: C22H23ClFN5O3. Mole weight: 459.91. Custom synthesis is available. Send your inquiries for more information. | London |
| AZD-9291 | AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. AZD 9291 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 = 480 nM). It binds the related IGF1R and hERG receptors with significantly reduced potency (IC50s = 2.9 and 16.2 μM, respectively). Uses: For research used only. Group: Pharmaceutical. Alternative Names: Mereletinib; AZD9291; AZD 9291; Osimertinib. CAS No. 1421373-65-0. Pack Sizes: 2.5 g. Product ID: B0084-462147. Molecular formula: C28H33N7O2. Mole weight: 499.61. Custom synthesis is available. Send your inquiries for more information. | London |
| Dacomitinib | Dacomitinib, aslo known as PF-299 and PF-00299804; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types. Group: Pharmaceutical. Alternative Names: dacomitinib; PF-00299804; PF00299804; PF 00299804; PF299804; PF-299804; PF 299804; PF-299; PF 299; PF299. CAS No. 1110813-31-4. Pack Sizes: 250 mg. Product ID: B0084-452473. Molecular formula: C24H25ClFN5O2. Mole weight: 469.945. Custom synthesis is available. Send your inquiries for more information. | London |
| Desmethyl Erlotinib | A metabolite of Erlotinib. Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity. Group: Pharmaceutical. Alternative Names: 2-[[4-[(3-Ethynylphenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]oxy]ethanol. CAS No. 183321-86-0. Pack Sizes: 5 mg. Product ID: B2694-263407. Molecular formula: C21H21N3O4. Mole weight: 379.42. Custom synthesis is available. Send your inquiries for more information. | London |
| Erlotinib-3-vinyl Hydrochloride | A metabolite of Erlotinib. Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity. Group: Pharmaceutical. Alternative Names: 6,7-Bis(2-methoxyethoxy)-N-(3-vinylphenyl)quinazolin-4-amine hydrochloride; 4-Quinazolinamine, N-(3-ethenylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1). CAS No. 1624294-38-7. Pack Sizes: 25 mg. Product ID: B1370-173396. Molecular formula: C22H26ClN3O4. Mole weight: 431.91. Custom synthesis is available. Send your inquiries for more information. | London |
| Erlotinib-[d6] Hydrochloride | Erlotinib-[d6] Hydrochloride is the labelled analogue of Erlotinib. Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity. Erlotinib is a medication used to treat non-small cell lung cancer and pancreatic cancer. Group: Pharmaceutical. Alternative Names: N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy-d3)-4-quinazolinamine Hydrochloride; 6,7-Bis(2-methoxyethoxy-d3)-4-(3-ethynylanilino)quinazoline Hydrochloride; [6,7-Bis(2-methoxyethoxy-d3)quinazolin-4-yl]-(3-ethynylphenyl)amine Hydrochloride; Erlotinib D6 Hydrochloride. CAS No. 1189953-78-3. Pack Sizes: 5 mg. Product ID: BLP-006076. Molecular formula: C22H18D6ClN3O4. Mole weight: 435.93. Custom synthesis is available. Send your inquiries for more information. | London |
| Erlotinib Impurity 8 | A metabolite of Erlotinib. Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity. Group: Pharmaceutical. Alternative Names: N-(3-Desethynylphenyl)-N-(3-bromophenyl) Erlotinib; N-(3-bromophenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. CAS No. 328528-74-1. Pack Sizes: 25 mg. Product ID: B2694-471125. Molecular formula: C20H22BrN3O4. Mole weight: 448.32. Custom synthesis is available. Send your inquiries for more information. | London |
| Icotinib | Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Group: Pharmaceutical. Alternative Names: BPI-2009H. CAS No. 610798-31-7. Pack Sizes: 300 mg. Product ID: B0084-459334. Molecular formula: C22H21N3O4. Mole weight: 391.42. Custom synthesis is available. Send your inquiries for more information. | London |
| Icotinib hydrochloride | Icotinib Hydrochloride is a quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), which is upregulated in a variety of cancer cell types. Icotinib supresses the cancer cell proliferation via EGFR tyrosine kinase inhibition. Group: Pharmaceutical. Alternative Names: Icotinib HCl; BPI-2009; BPI 2009; BPI2009. CAS No. 1204313-51-8. Pack Sizes: 300 mg. Product ID: BBF-04036. Molecular formula: C22H22ClN3O4. Mole weight: 427.88. Custom synthesis is available. Send your inquiries for more information. | London |
| Irbinitinib | Irbinitinib,also known as ARRY-380 and ONT-380, is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation. Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: ARRY-380; ARRY 380; ARRY380; ONT-380; ONT-380; ONT-380. CAS No. 937263-43-9. Pack Sizes: 100 mg. Product ID: B0084-462666. Molecular formula: C26H24N8O2. Mole weight: 480.532. Custom synthesis is available. Send your inquiries for more information. | London |
| JNJ-26483327 | JNJ-26483327 is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). By inhibiting several different signaling molecules that play crucial roles at various stages in tumorigenesis, this agent may inhibit tumor growth, invasion, migration and metastasis. In addition, JNJ-26483327 crosses the blood-brain barrier (BBB). Group: Pharmaceutical. Alternative Names: JNJ-26483327; JNJ 26483327; JNJ26483327. CAS No. 807640-87-5. Pack Sizes: 10 mg. Product ID: B0084-462547. Molecular formula: C22H25BrN4O2. Mole weight: 457.372. Custom synthesis is available. Send your inquiries for more information. | London |
| Lapatinib Ditosylate | Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: GW-572016; GW 572016; GW572016. CAS No. 388082-77-7. Pack Sizes: 1 g. Product ID: B0084-067756. Molecular formula: C29H26ClFN4O4S.2C7H8O3S. Mole weight: 925.46. Custom synthesis is available. Send your inquiries for more information. | London |
| Lavendustin A | Lavendustin A is an epidermal growth factor receptor inhibitor tyrosine kinase with IC50 value of 11 nM. Group: Pharmaceutical. Alternative Names: Lavendustin A; RG 14355; RG-14355; RG14355; 5-[[(2,5-Dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid. CAS No. 125697-92-9. Pack Sizes: 10 mg. Product ID: B0084-047820. Molecular formula: C21H19NO6. Mole weight: 381.38. Custom synthesis is available. Send your inquiries for more information. | London |
| Methyl 2,5-dihydroxycinnamate | Methyl 2,5-dihydroxycinnamate, a stable analog of erbstatin, is a stable, potent inhibitor of EGFR kinase activity. It is described to be four-times more stable than erbstatin in calf serum2. It was shown to delay the S-phase induction by epidermal growth factor in quiescent normal rat kidney cells, without affecting the total amount of DNA synthesis. Group: Pharmaceutical. Alternative Names: Methyl 2,5-dihydoxycinnamate; 3-(2,5-dihydroxyphenyl)-2-propenoic acid, methyl ester; Erbstatin Analog. CAS No. 63177-57-1. Pack Sizes: 100 mg. Product ID: B0084-012976. Molecular formula: C10H10O4. Mole weight: 194.19. Custom synthesis is available. Send your inquiries for more information. | London |
| Naquotinib | Naquotinib is an irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity with IC50 of 8-33 nM toward EGFR mutants. Group: Pharmaceutical. Alternative Names: ASP 8273; ASP8273; ASP-8273; (R)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide. CAS No. 1448232-80-1. Pack Sizes: 5 mg. Product ID: B0084-475727. Molecular formula: C30H42N8O3. Mole weight: 562.719. Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyl Vandetanib | N-Desmethyl Vandetanib is a metabolite of Vandetanib. Vandetanib is an antitumor drug used for the treatment of medullary thyroid cancer. Vandetanib effects through inhibiting vascular endothelial growth factor receptor-2 (VEGFR), epidermal growth factor receptor (EGFR) and the RET-tyrosine kinase activity. Group: Pharmaceutical. Alternative Names: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)-4-quinazolinamine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(piperidin-4-yl)methoxy]quinazoline. CAS No. 338992-12-4. Pack Sizes: 5 mg. Product ID: B1926-260255. Molecular formula: C21H22BrFN4O2. Mole weight: 461.34. Custom synthesis is available. Send your inquiries for more information. | London |
| Neratinib | Neratinib, also known as HKI-272 or PB272, is an orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells. Group: Pharmaceutical. Alternative Names: 2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide; (E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide; (E)-N-[4-[[3-Chloro-4-((pyridin-2-yl)meth. CAS No. 698387-09-6. Pack Sizes: 500 mg. Product ID: B0084-347125. Molecular formula: C30H29ClN6O3. Mole weight: 557.04. Custom synthesis is available. Send your inquiries for more information. | London |
| Olmutinib | Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK). Group: Pharmaceutical. Alternative Names: N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; HM61713; HM 61713; HM-61713; BI 1482694; BI-1482694; BI1482694; Olmutinib. CAS No. 1353550-13-6. Pack Sizes: 200 mg. Product ID: B0084-470842. Molecular formula: C26H26N6O2S. Mole weight: 486.18. Custom synthesis is available. Send your inquiries for more information. | London |
| Osimertinib-[d6] | Osimertinib-[d6], is an isotope labelled derivative of Osimertinib. Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor drug used to treat non-small-cell lung carcinomas. Group: Pharmaceutical. Alternative Names: Osimertinib D6. CAS No. 1638281-44-3. Pack Sizes: 10 mg. Product ID: BLP-004457. Molecular formula: C28H27D6N7O2. Mole weight: 505.66. Custom synthesis is available. Send your inquiries for more information. | London |
| Recombinant IGF-I (human) | Recombinant IGF-I (human) is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) and inhibits its activity. Group: Pharmaceutical. Alternative Names: Recombinant human insulin-like growth factor-1; Human IGF-I; Insulin-like Growth Factor-I (E3R) human; rec IGF-I (human). CAS No. 67763-96-6. Pack Sizes: 1 mg. Product ID: BAT-010854. Custom synthesis is available. Send your inquiries for more information. | London |
| Rociletinib | Rociletinib is a third-generation irreversible kinase inhibitor of epidermal growth factor receptor (EGFR). Rociletinib was shown to inhibit the proliferation of non-small cell lung cancer (NSCLC) cells expressing mutant EGFR. It also exhibits anti-tumor activity in NSCLC EGFR mutant xenograft models. Group: Pharmaceutical. Alternative Names: CO-1686; CO1686; CO 1686; AVL-301; AVL 301; AVL301; CNX-419; CNX 419; CNX419; N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide. CAS No. 1374640-70-6. Pack Sizes: 100 mg. Product ID: B0084-462150. Molecular formula: C27H28F3N7O3. Mole weight: 555.562. Custom synthesis is available. Send your inquiries for more information. | London |
| (S)-N-Boc-3-(Hydroxymethyl)morpholine | An intermediate of BMS-599626, a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. Group: Pharmaceutical. Alternative Names: (S)-4-Boc-(3-hydroxymethyl)morpholine; (S)-tert-butyl 3-(hydroxymethyl)morpholine-4-carboxylate; (S)-N-BOC-3-hydroxymethylmorpholine; 3(S)-Hydroxymethyl-4-Boc-morpholine. CAS No. 714971-28-5. Pack Sizes: 10 g. Product ID: BB034402. Molecular formula: C10H19NO4. Mole weight: 217.26. Custom synthesis is available. Send your inquiries for more information. | London |
| SU5408 | A potent, selective and cell-permeable inhibitor of VEGFR2 kinase(IC50= 70 nM) with little or no effect against receptors for platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor (IC50 > 100 μM). Group: Pharmaceutical. Alternative Names: SU-5408; SU 5408; SU5408; ethyl 2,4-dimethyl-5-[(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrole-3-carboxylate; VEGFR2 Kinase Inhibitor I; IN1018. CAS No. 15966-93-5. Pack Sizes: 25 mg. Product ID: B2693-312027. Molecular formula: C18H18N2O3. Mole weight: 310.35. Custom synthesis is available. Send your inquiries for more information. | London |
| Tacalcitol monohydrate | Tacalcitol is a vitamin D analogue that promotes normal bone development by regulating calcium. It modulates immunological and inflammatory processes and induces nerve growth factor production in epidermal keratinocytes. Group: Pharmaceutical. Alternative Names: 1,24(R)-Dihydroxyvitamin D3, monohydrate. CAS No. 93129-94-3. Pack Sizes: 5 mg. Product ID: B2693-100725. Molecular formula: C27H46O4. Mole weight: 434.65. Custom synthesis is available. Send your inquiries for more information. | London |
| Tectorigenin | Tectorigenin induced differentiation of human promyelocytic leukemia HL-60 cells to granulocytes and monocytes/macrophages, and caused apoptotic changes of DNA in the cells, as did genistein. Tectorigenin also inhibited autophosphorylation of epidermal growth factor (EGF) receptor by EGF and decreased the expression of Bcl-2 protein, with less activity than genistein. From these results, tectorigenin may be a possible therapeutic agent for leukemia. Uses: Antioxidant. Group: Pharmaceutical. Alternative Names: 5,7-Dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one; 6-Methoxy-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-; Isoflavone, 4',5,7-trihydroxy-6-methoxy-; 5,7,4'-Trihydroxy-6-methoxyisoflavone; K 251T; Tectrigenin. CAS No. 548-77-6. Pack Sizes: 100 mg. Product ID: NP2537. Molecular formula: C16H12O6. Mole weight: 300.26. Custom synthesis is available. Send your inquiries for more information. | London |
| Trastuzumab emtansine | Trastuzumab emtansine is an antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surface surfaces. Upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers. Group: Pharmaceutical. CAS No. 1018448-65-1. Pack Sizes: 5 mg. Product ID: BADC-00023. Molecular formula: C6448H9948N1720O2012S44·(C47H62ClN4O13S)n. Custom synthesis is available. Send your inquiries for more information. | London |
| Retinyl acetate | Retinyl acetate is a natural form of vitamin A, a group of unsaturated nutritional organic compounds that includes retinol, retinal, retinoic acid, as well as several provitamin A carotenoids and beta-carotene. Vitamin A has multiple functions: it is important for growth and development, for the maintenance of the immune system and good vision. Vitamin A is needed by the retina of the eye in the form of retinal, which combines with protein opsin to form rhodopsin, the light-absorbing molecule necessary for both low-light (scotopic vision) and color vision. It also functions as retinoic acid (an irreversibly oxidized form of retinol), which is an important hormone-like growth factor for epithelial and other cells. It can absorb through the skin, resist keratinization, stimulate the growth of collagen and elastin, and increase the thickness of the epidermis and dermis. It enhances skin elasticity, effectively eliminates wrinkles, promotes skin renewal, and maintains skin vitality. It is used in eye cream, moisturizer, repair cream, shampoo, conditioner, etc. Uses: Ingredient of health care products. Group: Pharmaceutical. Alternative Names: Vitamin A acetate; Retinol Acetate; Retinol acetate; All-trans-Retinyl acetate; Retinol, acetate. CAS No. 127-47-9. Pack Sizes: 1 kg. Product ID: B1370-464906. Molecular formula: C22H32O2. Mole weight: 328.5. Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
